MBMathias Bressel

Mathias Bressel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mathias Bressel has a total of 133 co-authors. Here are the top co-authors by number of shared publications:

  • Tomas Kron

    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Centre for Medical Radiation Physics, University of Wollongong, Wollongong, Australia

    6 shared publications
  • Farshad Foroudi

    Department of Radiation Oncology ONJ Centre, Austin Health Heidelberg Victoria Australia

    5 shared publications
  • Nicholas Hardcastle

    Peter MacCallum Cancer Centre

    4 shared publications
  • Shankar Siva

    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia

    4 shared publications
  • Chen Liu

    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

    3 shared publications
  • David Ball

    Department of Radiation Oncology, Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia

    3 shared publications

Latest Publications

  • Open Access

    Applying Radiomics to Predict Outcomes in Patients with High-Grade Retroperitoneal Sarcoma Treated with Preoperative Radiotherapy

    by Adel Shahnam, Nicholas Hardcastle, David E. Gyorki, Katrina M. Ingley, Krystel Tran, Catherine Mitchell, Sarat Chander, Julie Chu, Michael Henderson, Alan Herschtal, et al.

    Retroperitoneal sarcomas (RPS) are rare tumours, primarily treated with surgical resection. However, recurrences are frequent. Combining clinical factors with CT-derived radiomic features could enhance treatment stratification and personalization. This study aims to assess whether radiomic features provide additional prognostic value beyond clinicopathological features in patients with high-risk RPS treated with preoperative radiotherapy. This retrospective study included patients aged 18 or older with non-recurrent and non-metastatic RPS treated with preoperative radiotherapy between 2008 and 2016. Hazard ratios (HR) were calculated using Cox proportional hazards regression to assess the impact of clinical and radiomic features on time to event outcomes. Predictive accuracy was assessed with c-statistics. Radiomic analysis was performed on the high-risk group (undifferentiated pleomorphic sarcoma, well-differentiated/de-differentiated liposarcoma or grade 2/3 leiomyosarcoma). Seventy-two patients were included, with a median follow-up of 3.7 years, the 5-year overall survival (OS) was 67%. Multivariable analysis showed older age (HR: 1.3 per 5-year increase, p = 0.04), grade 3 (HR: 180.3, p = 0.02), and larger tumours (HR: 4.0 per 10 cm increase, p = 0.02) predicted worse OS. In the higher-risk group, the c-statistic for the clinical model was 0.59 (time to distant metastasis (TDM)) and 0.56 (OS). Among 27 radiomic features, kurtosis improved OS prediction (c-statistic 0.69, p = 0.013), and Neighbourhood Gray-Tone Difference Matrix (NGTDM) busyness improved it to 0.73 (p = 0.036). Kurtosis also improved TDM prediction (c-statistic 0.72, p = 0.023). Radiomic features may complement clinicopathological factors in predicting overall survival and time to distant metastasis in high-risk retroperitoneal sarcoma. These exploratory findings warrant validation in larger, multi-institutional studies.

  • An International Lymphoma Radiation Oncology Group Study of Radiation Therapy for Bilateral Indolent Orbital Adnexal Lymphomas

    by Krystel Tran, Dongryul Oh, Richard Tsang, Chang-Ok Suh, Hong In Yoon, Hwa Kyung Byun, Senzo Taguchi, Jillian R. Gunther, Bouthaina Dabaja, Chelsea C. Pinnix, et al.


  • Patient- and Clinician-Reported Outcomes in Human Papillomavirus-Associated Tonsillar Carcinoma Treated With Unilateral and Bilateral Intensity Modulated Radiation Therapy–A Substudy From TROG 12.01

    by Lachlan McDowell, Danny Rischin, Madeleine King, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E. Jackson, Mathias Bressel, Tsien Fua, et al.


  • Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort

    by Lachlan McDowell, Georgina Casswell, Mathias Bressel, Allison Drosdowsky, Danny Rischin, Andrew Coleman, Sudichhya Shrestha, Ieta D'COsta, Tsien Fua, Albert Tiong, et al.


  • Open Access

    Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy

    by Michael P. MacManus, Rodney J. Hicks, Mathias Bressel, Belinda A. Campbell, Andrew Wirth, Gail Ryan, H. Miles Prince, Max Wolf, Rachel Brown, John F. Seymour

    Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic series describe long-term disease-free survival in stage III disease treated with wide-field radiation therapy (WFRT), encompassing all known disease sites. We report outcomes for patients staged with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and treated with CT-planned WFRT, given as either comprehensive lymphatic irradiation (CLI) or total nodal irradiation (TNI). This analysis of a prospective cohort includes PET-staged patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24–30Gy between 1999 and 2017. Fifteen patients also received planned systemic therapy (containing rituximab in 11 cases) as part of their primary treatment. At 10 years, overall survival and freedom from progression (FFP) were 100% and 75%, respectively. None of the 11 rituximab-treated patients have relapsed. Nine relapses occurred; seven patients required treatment, and all responded to salvage therapies. A single death occurred at 16 years. The principal acute toxicity was transient hematologic; one patient had residual grade two toxicity at one year. With FDG-PET staging, most patients with stage III FL experience prolonged FFP after WFRT, especially when combined with rituximab.


  • Open Access

    Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma

    by Lachlan McDowell, Georgina Casswell, Mathias Bressel, Karla Gough, Allison Drosdowsky, Andrew Coleman, Sudi Shrestha, Ieta D'COsta, Tsien Fua, Albert Tiong, et al.


  • Open Access

    Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides

    by Belinda A. Campbell, Gail Ryan, Christopher McCormack, Eleanor Tangas, Mathias Bressel, Robert Twigger, Odette Buelens, Carrie van der Weyden, H. Miles Prince

    Mycosis fungoides (MF) and Sezary syndrome (SS) are multi-relapsing, morbid, cutaneous T-cell lymphomas. Optimal treatment sequencing remains undefined. Total skin electron therapy (TSE) is a highly technical, skin-directed treatment, uniquely producing symptom-free and treatment-free intervals. Recent publications favour low-dose TSE for reduced toxicity, but early data support conventional-dose TSE (cdTSE) for longer disease control. Patient selection requires weighing-up tolerability against response durability. We investigated duration of benefit from cdTSE in patients with poorer prognosis diseases: SS and heavily pre-treated MF. Endpoints were overall survival, and “time to next treatment” (TTNT) as surrogate for clinical benefit duration. Seventy patients (53 MF, 17 SS) were eligible: median prior treatments, 4; median cdTSE dose, 30 Gy; median follow-up, 5.8 years. SS patients had worse prognosis (HR = 5.0, p < 0.001) and shorter TTNT (HR = 4.5, p < 0.001) than MF patients; median TTNT was only 3.7 months. Heavily pre-treated MF patients had inferior prognosis (HR = 1.19 per additional line, p = 0.005), and shorter TTNT (HR = 1.13 per additional line, p = 0.031). Median TTNT for MF patients with ≥3 prior treatments was 7.1 months, versus 23.2 months for 0–2 prior treatments. In conclusion, cdTSE has a limited role in SS. TTNT is reduced in heavily pre-treated MF patients, suggesting greater benefit when utilized earlier in treatment sequencing.


  • Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis

    by Nicholas W. Bucknell, Nicholas Hardcastle, Mathias Bressel, Michael S. Hofman, Tomas Kron, David Ball, Shankar Siva


  • Open Access

    TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

    by Shankar Siva, Brent Chesson, Mathias Bressel, David Pryor, Braden Higgs, Hayley M. Reynolds, Nicholas Hardcastle, Rebecca Montgomery, Ben Vanneste, Vincent Khoo, et al.

    Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC. FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours > 4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies. The present study design allows for multicentre prospective validation of the efficacy of SABR for primary RCC that has been observed from prior single institutional and retrospective series. The study also allows assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and renal function post therapy. Clinicaltrials.gov NCT02613819 , registered Nov 25th 2015.


  • Patterns of health services utilization in the last two weeks of life among cancer patients: Experience in an Australian academic cancer center

    by Wee Loon Ong, Richard Khor, Mathias Bressel, Phillip Tran, Jo Tedesco, Keen Hun Tai, David Ball, Gillian Duchesne, Farshad Foroudi

    To report the trend in end-of-life health services (HS) utilization among cancer patients treated in a large Australian academic cancer center over a 12-year period. This is a retrospective study of cancer patients treated at the Peter MacCallum Cancer Centre (PMCC), who had documented death between January 2002 and December 2013. Using administrative and billing database, we report on the utilization of different categories of HS within two weeks of death: diagnostic investigations (pathology and radiology), inpatient and outpatient services, and potentially futile interventions (PFI, which include radiotherapy, chemotherapy and surgery). Of the 27 926 “active” cancer patients in the study (i.e. those with medical contact at PMCC in the last year of life), 6368 (23%) had documented HS utilization within two weeks of death. 11% and 9% had pathology and radiology investigations respectively, 14% had outpatient clinic appointments, and 7% had hospital admissions. There were 2654 patients (10%) who had PFI within two weeks of death – 2198 (8%) had radiotherapy, 287 (1%) chemotherapy and 267 (1%) surgery. We observed peak HS and PFI utilization in 2004, which then dropped to its lowest in 2009/2010. Experience in an Australian cancer center suggests approximately one in four “active” cancer patients had HS utilization, and one in ten had PFI, within two weeks of death. The implementation of palliative care guidelines may reduce some of these potentially wasteful and futile interventions.